Schizophrenia/Psychosis

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Learn more about the latest advancements in schizophrenia treatment and the ongoing battle against stigma during Mental Health Awareness Month.

Check out the pipeline updates from April!

Peter J. Weiden, MD, discusses the latest Cobenfy data and implications for schizophrenia treatment.

Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Different medications for different domains: new treatments are changing the way schizophrenia is managed.

Take a look at the differentiation between prodrome and attenuated psychosis, along with cognitive impairment associated with schizophrenia.

Here's what patients should know about Cobenfy for the treatment of schizophrenia.

Without the scaffolding of the REMS requirement for clozapine, how can you best utilize this treatment?

How can you best transition patients to Cobenfy if they are already taking an antipsychotic medication?

Peripartum psychosis is considered a psychiatric emergency. Here is how an interdisciplinary team can provide the best care.

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

How does John Kane, MD, address issues of cognition in schizophrenia?

SPG302, a regenerative treatment for schizophrenia, could reset the clock on the brain.

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

Treatments that target negative and cognitive symptoms of schizophrenia could put patients in better control of their life.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

While the removal of the REMS requirement can be liberating, appropriate monitoring for patients with schizophrenia is still of the utmost importance.

The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.